Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

When 1+1 = 3: Unlocking the potential of the IL-2 pathway with NKTR-214 in combination treatment

Date

15 Dec 2018

Session

Immuno-oncology: State of the art I

Presenters

Jonathan Zalevsky

Authors

J. Zalevsky

Author affiliations

  • Biology, Nektar Therapeutics, 94158 - San Francisco/US
More

Resources

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings